Skip to main content
Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

HOME
ABOUT
AREAS OF FOCUS
- Close
- PIPELINE
- POSTERS & PUBLICATIONS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
CONTACT US

Main Content

ADVANCING ANTIBODY DRUG

CONJUGATES WITH NOVEL

IMMUNO-ONCOLOGY PAYLOADS

CORPORATE PRESENTATION CORPORATE PRESENTATION ANNUAL GENERAL MEETING 2026 ANNUAL GENERAL MEETING 2026

RECENT PRESS RELEASES

Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

July 21, 2026

Akari Therapeutics Appoints Former AACR President andRenowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

July 7, 2026

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

June 29, 2026

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026

June 4, 2026

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

May 28, 2026

Footer

FOLLOW US

Privacy Statement

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.